BioSpace News Archive

SalioGen Therapeutics, a privately held biotechnology company, today announced that its Board of Directors has appointed Jason F. Cole, J.D. as Chief Executive Officer (CEO).

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will hold a Capital Markets Day on October 17, 2023.

Crossject, a specialty pharma company developing needle-free autoinjectors for emergency situations, announces a significant improvement in its ESG Gaïa rating, achieving a score of 73/100.

The strategic collaboration between Curadh MTR Inc. and SHINE Technologies marks a pivotal moment in the advancement of cancer therapies.

Results from the primary analysis of the DESTINY-Lung02 phase 2 trial showed ENHERTU® continued to demonstrate strong and durable tumor responses in previously treated patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer.

Medivir AB announced that Medivir’s partner Tango Therapeutics has received FDA clearance on its Investigational New Drug application for TNG348.

Eagle Pharmaceuticals, Inc. has been selected for a poster presentation at the conference co-sponsored by the American Society for Microbiology (“ASM”) and the European Society for Clinical Microbiology and Infectious Diseases (“ESCMID”).

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) today announced positive interim masked safety data for its lead product candidate EYP-1901 from the Company’s ongoing Phase 2 PAVIA trial evaluating EYP-1901 as a potential nine-month treatment for moderately-severe to severe non-proliferative diabetic retinopathy (NPDR) and DAVIO 2 trial as a potential six-month sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD).

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndrome (ARDS), today announced clinical data from the discontinued Phase 3 ARTEST clinical trial of enobosarm monotherapy for the 3rd line or greater in the metastatic setting of AR+ER+HER2- breast cancer.

Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications.